Reimagining Medicine
Company overview
Financial review
2023 priorities
Appendix
FINANCIAL PROFILE
Sandoz returns to growth in 2022; planned spin-off on track for H2
Driven by Biopharma and ex-US sales
FY performance¹
Sales USD 9.2bn (+4%)
Biopharma grew 9% and Retail 4%
Strong ex-US sales growth:
■ EU: USD 4.9bn (+4%)
■ ROW: USD 2.5bn (+9%)
■ US: USD 1.8bn (-4%)
Core Oplnc (-1%) impacted by inflationary
pressures on input costs and higher SG&A
Key growth drivers
for 2023 and beyond
Share gains across geographies
Two potential US biosimilar
approvals expected in H2 2023
Launches, targeting USD 80bn
originator sales (2030) with strong
pipeline of 15+ biosimilar assets
Bolt-on BD&L and M&A
On track for planned
spin-off in H2 2023
Final transaction requires Novartis
AG BoD and shareholder approval
Carve-out financials to be
provided ahead of CMD
Expected to be tax neutral
to Novartis and the majority of our
institutional shareholders
1. All growth rates in constant currencies (cc).
40 Investor Relations | Q4 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation